Skip to main content

Table 1 Pigment epithelium-derived factor expression in normal versus breast tumor tissue samples

From: Loss of pigment epithelium-derived factor: a novel mechanism for the development of endocrine resistance in breast cancer

Tissue sample n PEDF status Intensity score
Recurrence tumors 28 (47.6%)a Positive > 150
  31 (52.4%)b Negative ≤ 25
Primary tumors 40 (67.8%)a Positive > 150
  19 (32.2%)b Negative ≤ 25
Endocrine-responsive tumors 125 (83.3%)c Positive > 150
  25 (16.7%)d Negative ≤ 25
Normal tissue 5 (100%) Positive ≥ 200
  0 (0%) Negative ≤ 25
  1. A total of 209 breast cancer patients were initially treated with tamoxifen and 59 patients developed recurrence disease after a mean follow-up of 93 months. Immunohistochemistry (IHC) staining was performed on tissue microarrays (TMAs) constructed from recurrence breast tumors (n = 59) and matched primary breast tumors (n = 59). Normal background breast tissue was also used for comparison. TMAs were also constructed from endocrine-responsive tumor tissues (n = 150). A semi-automated quantitative image analysis system (ACIS II) was used to quantitate the staining of the TMA slides. For IHC analysis, pigment epithelium-derived factor (PEDF) staining was quantified as an intensity score (scale 0 to 255). aP < 0.00003, number of PEDF-positive recurrence tumors versus PEDF-positive primary tumors. bP < 0.000001, number of PEDF-negative recurrence tumors versus PEDF-negative primary tumors. cP < 0.00008, number of PEDF-positive recurrence tumors versus PEDF-positive endocrine-responsive tumors. dP < 0.000001, number of PEDF-negative recurrence tumors versus PEDF-negative endocrine-responsive tumors.